Skip to content

Lung ILC Core Evidence Synthesis

Scope

This digest provides a biology-first map of the strongest source-linked evidence currently supporting the ILC-in-lung wiki. It integrates lung and airway ILC sources across ILC2 and ILC3 disease roles, regulatory mechanisms, tissue context, and translational boundaries.

The digest is designed as a reusable orientation page: a reader should be able to understand the main lung ILC claims without needing to know the project history behind each source note. Project history remains traceable through project-note and log pages.

Evidence tags

#digest/core_evidence #tissue/lung #tissue/airway #cell/ILC2 #cell/ILC3 #cell/ILC1 #cell/fibroblast #cell/eosinophil #cell/macrophage #disease/asthma #disease/infection #disease/ARDS #disease/COPD #axis/ILC_lung_infection #axis/ILC_airway_inflammation #axis/ILC_plasticity #axis/ILC_regulation #axis/human_lung_ILC

Working model

The current focused evidence supports a lung ILC model organized around context, not around a single fixed function. ILC2s and ILC3s act as tissue-sensitive immune modules whose outputs depend on disease setting, tissue compartment, stimulus, timing, and regulatory niche.

ILC2s are best understood as lung and airway signal integrators. In allergic airway disease, they amplify type 2 inflammation through IL-5, IL-13, lipid mediators, epithelial alarmins, memory-like behavior, and eosinophil feedback. In respiratory viral disease, they can drive airway hyperreactivity, but they can also support repair or reprogram macrophage niches depending on the virus and time point. Their function is tuned by neuroimmune signals, costimulatory pathways such as ICOS:ICOSL, OX40L, and PD-L1, autophagy-supported metabolism, checkpoint pathways, microbial metabolites, stromal or mechanical cues, interorgan trafficking, adaptive Treg feedback, and LIF-linked immune-cell egress. They also occupy structured stromal and peribronchovascular niches rather than acting as freely distributed effector cells, and interferon-rich settings can directly restrain their expansion, positioning, or effector output. Pulmonary evidence also shows that IL-33-activated ILC2-derived IL-13 can reprogram tissue-resident alveolar macrophages toward an IRF4-driven inflammatory niche state. Allergic-asthma evidence adds an IL-9/Blimp-1 state-fidelity axis that maintains type 2 ILC2 output while restraining type 1 cytokine deviation. Human severe-asthma sputum further links airway ILC2 signatures with reduced lung function and shows anti-IL-5/5Ralpha-associated suppression of IL-5+/IL-13+ airway ILCs without core ILC subset depletion. This makes ILC2 biology broader than a simple "type 2 cytokine cell" model.

ILC3s are best understood as IL-22/IL-17-capable cells whose lung roles split into protective/developmental and inflammatory branches. In bacterial infection and newborn lung biology, ILC3s can support barrier defense and developmental niches. In ARDS-like injury, neutrophilic asthma, smoking-associated asthma, and steroid-resistant asthma, ILC3-related IL-17A, neutrophil chemoattractants, glucocorticoid resistance, and stromal SCF/KIT signaling become central. Around those pulmonary branches sits a broader mechanism layer, mostly defined in gut or mucosal studies, in which AHR and WASH support identity, vitamin D restrains IL-23 signaling, CD71-linked iron handling plus NPM1-, BACH2/PPARgamma-, and LINGO4-linked mitochondrial fitness support maintenance, IRE1alpha/XBP1 sustains inflammatory cytokine output, IL-17D/CD93 supports IL-22 programs, and PDGF-D responses are species- and receptor-context dependent. However, IL-17-producing ILC-like cells require careful classification because some IL-17-producing states may reflect ILC2/ILC3 boundary biology rather than stable canonical ILC3s. Adaptive-immunity regulation now has a distinct evidence layer. The lung-direct anchors are mouse ILC2 PD-L1 control of Th2 polarization, ILC2 OX40L control of local Th2/Treg expansion, and ILC2-supported Gata3high Treg feedback that restrains effector-memory Th2 expansion in type 2 inflammation. ILC3 adaptive-immunity mechanisms are stronger in gut, tonsil, and blood: MHCII-positive ILC3s can restrain commensal-specific CD4 T cells, intestinal ILC3s can maintain or select Tregs through IL-2 and antigen-presentation-linked programs, and human CD40L-positive ILC3s can support regulatory B-cell differentiation. These mechanisms are important for the conceptual map, but most are not yet direct pulmonary evidence; see ILC Regulation Of Adaptive Immunity.

flowchart TB
    accTitle: Lung ILC Core Map
    accDescr: Compact map separating ILC2 and ILC3 state branches in lung and airway disease. Detailed mediators are described in the prose below the diagram.

    tissue["Lung/airway context"] --> ilc2["ILC2 states"]
    tissue --> ilc3["ILC3 states"]

    ilc2 --> allergic["Type 2 disease"]
    ilc2 --> viral["Viral outcomes"]
    ilc2 --> regulation["Regulatory axes"]
    ilc2 --> plasticity["Boundary states"]

    ilc3 --> defense["Defense/development"]
    ilc3 --> injury["Inflammatory disease"]
    ilc3 --> stromal["Stromal licensing"]
    ilc3 --> caution["Classification caution"]

    classDef tissue_class fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef ilc2_class fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef ilc3_class fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef branch fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d

    class tissue tissue_class
    class ilc2 ilc2_class
    class ilc3 ilc3_class
    class allergic,viral,regulation,plasticity,defense,injury,stromal,caution branch

Core claims

  • Lung ILC2s can drive airway hyperreactivity through innate, non-adaptive pathways, especially in IL-33/IL-13-linked respiratory viral or allergic contexts.
  • Lung ILC2s can also support repair and niche remodeling, including amphiregulin-linked epithelial repair and GM-CSF-dependent monocyte-derived alveolar macrophage imprinting in infection-conditioned settings.
  • Lung ILC2s can also remodel the alveolar niche more directly: in a recent pulmonary source, IL-33-activated ILC2-derived IL-13 reprogrammed tissue-resident alveolar macrophages from a PPARgamma-centered homeostatic state toward an IRF4-driven inflammatory program.
  • Lung ILC2s can be anatomically positioned in adventitial/peribronchovascular stromal niches supported by IL-33/TSLP-producing fibroblast-like cells, creating a spatial layer for type 2 activation and feedback.
  • IFN-gamma is a context-dependent ILC2 brake that can suppress IL-33-driven activation, constrain type 2 lymphocyte tissue dispersion, inhibit ILC2-driven AHR through TLR9/interferon/STAT1 signaling, or suppress protective ILC2 output during influenza.
  • ILC2 disease activity is regulated by epithelial alarmins, lipid mediators, neuroimmune cues, metabolic state, checkpoint pathways, microbial metabolites, and stromal or cellular feedback.
  • ILC2s can regulate adaptive type 2 immunity through OX40L-mediated local Th2 and Treg expansion in mouse lung type 2 inflammation.
  • ILC2s can also regulate adaptive Th2 polarization through a PD-L1:PD-1 contact pathway in mouse primary helminth-associated type 2 immunity.

  • ILC2-OX40L biology includes a restraint arm: Gata3high Tregs supported by ILC2 dialogue can feed back on OX40L availability and limit effector-memory Th2 expansion after allergen exposure.

  • Activated pulmonary ILC2s are also shaped by spatial guidance cues, including CCR8-CCL8 positioning signals and collagen-I-dependent migratory behavior in inflamed lung.

  • ILC2 neuroimmune regulation is receptor- and context-dependent rather than uniformly activating: some circuits amplify type 2 inflammation, whereas others support tissue-protective amphiregulin programs or constrain IL-13-dominant pathology.
  • Human lung contains identifiable ILC subsets, but human lung tissue, sputum, blood, nasal airway, and mouse lung evidence should not be treated as interchangeable.
  • Lung ILC3s can support IL-22-associated antibacterial defense and neonatal pulmonary niche development.
  • Lung ILC3s can also participate in IL-17A/neutrophil-rich inflammatory disease, including ARDS-like injury, neutrophilic asthma, smoking-associated asthma, and steroid-resistant asthma.
  • Lung ILC3/type 3 inflammation includes gut-lung and fungal-infection branches: dysbiosis can prime IL-23-linked lung ILC3/Th17 responses in mouse hypersensitivity pneumonitis, and pulmonary fungal infection can engage ILC sensing and ILC3-like plasticity (Microbial dysbiosis sculpts a systemic ILC3/IL-17 axis governing lung inflammatory responses and central hematopoiesis; Innate lymphoid cells integrate sensing and plasticity to control fungal infections).
  • Obesity-associated airway hyperreactivity adds a distinct NLRP3-IL-1beta-IL-17-producing innate-lymphoid branch to the ILC3 disease map.
  • Pulmonary fibroblast-derived SCF/KIT signaling is a focused stromal axis that can augment ILC3 IL-17A and neutrophilic asthma-like inflammation.
  • ILC3 regulation also includes restraint programs; current source-linked context includes a gut-labeled CTLA-4-positive ILC3 checkpoint branch downstream of IL-23.
  • ILC3 adaptive-immunity regulation includes gut-labeled MHCII/CD4 T-cell restraint, IL-2- and MHCII-linked Treg maintenance or selection, and a human tonsil/blood CD40L/BAFF/IL-15 regulatory B-cell branch.
  • ILC3 antigen-presentation outcomes are context-dependent across extrapulmonary sources: gut tolerance, CNS neuroinflammation, colon-cancer immunotherapy responsiveness, and RORgammat-positive DC boundary biology should not be collapsed into one lung ILC3 claim.

  • Gut/mucosal ILC3 source-reviewed context includes RANKL/RANK restraint, BMAL1 and light/brain circadian timing, FFAR2 metabolite sensing, VIP receptor-context neuroimmune circuits, trained defense states, and HB-EGF tissue protection; these are useful regulatory comparators rather than direct pulmonary evidence.

  • ILC3 regulation also includes identity, nutrient, and stress-support programs; current source-linked context includes AHR/WASH maintenance, vitamin D-mediated IL-23 restraint, a CD71-iron axis, and IRE1alpha/XBP1-dependent cytokine sustainment, though these mechanisms are currently best labeled as extrapulmonary or mucosal context unless matched lung evidence is present.

  • ILC2 regulation now has a stronger tissue-boundary layer: gut AHR and RXRgamma restrain intestinal ILC2 activation, ADM2 promotes tissue-protective AREG-positive ILC2 responses, tuft-cell IL-17RB restrains IL-25 bioavailability, and RORalpha marks a thymic lineage-commitment checkpoint. These sources refine mechanism vocabulary but should not be promoted to direct lung causality.

  • ILC plasticity is not a side issue: ILC2-to-ILC1-like conversion, memory-like ILC2s, IL-17-producing ST2+ ILC2s, c-Kit+ ILC2/ILC3-like states, severe-asthma sputum intermediate ILC2s, and memory-like ILC3s all shape interpretation.

Evidence layers

Evidence layer What it supports Main caution
Mouse perturbation models Strongest causal links between mediator, ILC state, and disease readout Translation to human asthma, COPD, ARDS, or infection requires tissue and disease matching
Human lung tissue Baseline presence and subset potential of pulmonary ILCs Often not causal by itself
Human sputum or airway sampling Disease-associated airway ILC states in asthma phenotypes Compartment differs from lung parenchyma and blood
Human nasal airway or polyp systems Useful airway plasticity comparator Should not be treated as lower-lung proof
Reviews and pathway syntheses Field-level framing and therapeutic hypotheses Need primary-source support before upgrading mechanistic confidence

Contradictions to track

  • ILC2s can be pathogenic, reparative, or niche-modifying depending on virus, allergen, timing, mediator output, and outcome readout.
  • ILC3 IL-22-associated defense and ILC3 IL-17A-associated pathology should not be collapsed into one "ILC3 protective" or "ILC3 pathogenic" model.
  • Human association and mouse perturbation answer different questions. The strongest wiki claims preserve whether the evidence is human tissue association, ex vivo function, mouse causality, or review-level synthesis.
  • SCF/c-Kit has distinct ILC2 and ILC3 branches. ILC2 SCF/c-Kit in chronic allergic disease should not be merged with fibroblast SCF/KIT-driven ILC3 IL-17A in neutrophilic asthma.
  • IL-17-producing ILC-like states may reflect bona fide ILC3s, ILC2-derived boundary states, or mixed gating contexts. Marker, lineage, and tissue labels are essential.
  • Human severe-asthma blood and sputum also require sex and compartment labels: female blood ILC/ILCP, ILC1, and ILC3 signals can diverge from male patterns, while airway ILC2 abundance relates more directly to lung function than blood ILC2 abundance (Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti-IL-5/5Ralpha biologics).

How to use this digest

Use this page as the first evidence synthesis layer after the homepage. For cell-specific detail, go to ILC2 or ILC3. For question-specific detail, go to ILC2 roles in pulmonary disease, ILC3 roles in pulmonary disease, ILC2 functional regulation mechanisms, or ILC3 functional regulation mechanisms. For a disease-first rearrangement of the same cross-subset material, use Lung ILC Disease Roles Companion.

Future Expansion Directions

  • Add human lung, BAL, bronchial biopsy, sputum, or spatial data that directly links ILC2/ILC3 states to asthma, COPD, ARDS, pneumonia, fibrosis, or lung cancer outcomes.
  • Add primary intervention evidence for ILC3-related steroid-resistant asthma or neutrophilic asthma targets before treating therapeutic claims as stronger evidence.
  • Revisit the ILC2 regulatory hierarchy if the same human cohort measures alarmins, neuroimmune receptors, metabolic programs, checkpoint molecules, and ILC2 cytokine output.
  • Revisit IL-17-producing ILC taxonomy when new lineage, fate-mapping, or single-cell multiome evidence separates bona fide ILC3s from plastic ILC2-derived states in lung disease.

Representative Source Spine

Viral disease, repair, and ILC2 lung function

ILC2 allergic inflammation, regulation, and plasticity

ILC regulation of adaptive immunity

ILC3 defense, injury, asthma, and classification

Lung overview and review orientation

Human baseline and airway translation

ILC2 niche, interferon brake, and type 2 circuit